EUVIMEDEUVIMED entdecken
Delphi-StudieOpen Access · CC BY 4.0

The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus

Daniel Piñeiro iD, José Ramón González-Juanatey iD, Ana Abreu iD, Enrique Gómez Alvarez iD, Carlos Ponte-Negretti iD, Burkhard Weisser iD, Alexander Parkhomenko iD, Francisco Araújo iD, Alvaro Sosa-Liprandi iD

Global Heart · 2025

DOI: 10.5334/gh.1466 ↗

Kurz gefasst

Delphi-Studie in der Zeitschrift Global Heart, 2025. Verfasst von Daniel Piñeiro und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Ramipril, Atorvastatin, Secondary Prevention, Aspirin. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The SECURE trial demonstrated that the cardiovascular (CV)-polypill (acetylsalicylic acid [ASA] + atorvastatin + ramipril) reduces CV mortality by 33% in patients with acute myocardial infarction compared to standard care. The 2023 ACS ESC Guidelines recommend the polypill to improve outcomes and adherence.

Objective

This study aims to establish a global consensus on the optimal use of the CV-polypill in secondary prevention.

Methods

A two-round, modified Delphi method was used, featuring a 30-statement evidence-based questionnaire validated by eight renowned cardiologists. Fifty clinicians from 19 countries in Europe, Latin America, and Asia were invited to join the Delphi panel. Panelists ranked responses using a three-point Likert scale for agreement and importance. Consensus was defined as ≥80% agreement or rating statements ‘very important’ or ‘important’. Statements without consensus after the first round were refined with evidence and feedback in the second round. Remaining disagreements were resolved in a face-to-face meeting. Descriptive statistics were applied.

Results

Response rate was 76% (round 1) and 74% (round 2); 82% were cardiologists, with 74% frequently recommending the CV-polypill. Consensus was achieved on 93.3% of statements. Research showing a 24% relative risk reduction in major adverse CV events over a median of 3 years with the CV-polypill post-acute myocardial infarction, compared to usual care, reached 97.4% agreement for clinical implementation, and a 100% consensus supported polypill use at hospital discharge or first follow-up visits; 81.1% agreed on a prompt initiation after patient stabilization. There was agreement on algorithms for initiating (97.3%), considering patient preferences (97.4%) to the polypill and its cost savings over usual care (89.5%).

Conclusion

The Delphi consensus on real-world use of a CV polypill (ASA, atorvastatin, and ramipril) for secondary prevention post-acute coronary syndrome supports early initiation (within 8 days or at discharge). The findings provide a foundation to inform practice and policy, identifying priorities for further research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RamiprilAtorvastatinSecondary PreventionAspirinCardiovascular DiseasesHumansDelphi TechniqueDrug CombinationsAngiotensin-Converting Enzyme InhibitorsDrug Therapy, CombinationHydroxymethylglutaryl-CoA Reductase Inhibitors

Stichwörter der Autor:innen

acute coronary syndrome treatmentcardiovascular polypillexpert consensusreal-world practicesecondary prevention

Substanzen

RamiprilAtorvastatinAspirinDrug CombinationsAngiotensin-Converting Enzyme InhibitorsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • School of Medicine, University of Buenos Aires, Argentina.
  • Hospital Clínico Universitario, Santiago de Compostela, Galicia, Spain.
  • Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
  • Instituto de Investigación Sanitaria de Santiago (IDIS) Santiago de Compostela, Galicia, Spain.
  • Centro de Reabilitação Cardiovascular, S. Cardiologia, Centro Hospitalar Universitário Lisboa Norte e Faculdade Medicina Universidade de Lisboa (FMUL), CAML, Lisbon, Portugal.
  • Instituto de Medicina Preventiva e Instituto de Saúde Ambiental da FMUL, Lisbon, Portugal.

ORCID-Profile: Daniel Piñeiro, José Ramón González-Juanatey, Ana Abreu, Enrique Gómez Alvarez, Carlos Ponte-Negretti, Burkhard Weisser, Alexander Parkhomenko, Francisco Araújo, Alvaro Sosa-Liprandi

Zitieren

APA

Piñeiro, D., González-Juanatey, J. R., Abreu, A., Alvarez, E. G., Ponte-Negretti, C., Weisser, B., Parkhomenko, A., Araújo, F., & Sosa-Liprandi, A. (2025). The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus. Global Heart. https://doi.org/10.5334/gh.1466

Vancouver

Piñeiro D, González-Juanatey JR, Abreu A, Alvarez EG, Ponte-Negretti C, Weisser B, et al. The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus. Global Heart. 2025. doi:10.5334/gh.1466

BibTeX
@article{Pieiro2025,
  author = {Piñeiro, Daniel and González-Juanatey, José Ramón and Abreu, Ana and Alvarez, Enrique Gómez and Ponte-Negretti, Carlos and Weisser, Burkhard and Parkhomenko, Alexander and Araújo, Francisco and Sosa-Liprandi, Alvaro},
  title = {The Polypill (Acetyl Salicylic Acid, Atorvastatin, and Ramipril) Paradigm Shift in Secondary Prevention: Global Expert Delphi Consensus},
  journal = {Global Heart},
  year = {2025},
  doi = {10.5334/gh.1466}
}
Kostenlos starten →